Business Trends– category –
-
Exosome Drug Delivery and Personalized mRNA Cancer Vaccines Emerge as Top Tech Trends for 2026, Showing Promise in Clinical Trials
Today Tech Times Global Overview Today Tech Times reports that exosome drug delivery systems (DDS) and personalized mRNA cancer vaccines are leading technology trends for 2026. Exosome DDS is the focus of over 200 ongoing clinical trials... -
Daiichi Sankyo & AstraZeneca’s Datroway Approved in EU as Only TROP2-Directed Medicine with Overall Survival Benefit for 1st-Line Metastatic TNBC Patients Ineligible for Immunotherapy
Business Wire USA Overview Datroway, a TROP2-directed antibody-drug conjugate (ADC) by Daiichi Sankyo and AstraZeneca, received EU approval for first-line treatment of metastatic triple-negative breast cancer (TNBC) patients not eligible... -
2026 RNA Therapeutics Transformation: FDA Approves ASO Olezarsen, siRNA Fitusiran & Plozasiran, Ushering in Diverse Nucleic Acid Era
MiraScope Unknown Overview The year 2026 marks a significant transformation in RNA therapeutics, with multiple approvals solidifying antisense oligonucleotide (ASO) and siRNA therapies as established treatment platforms. Ionis Pharmaceut... -
Ribo Life Science’s siRNA Therapy Vortosiran Receives EMA Approval for Stroke Prevention Trial in Atrial Fibrillation Patients
Insight, China's Pharmaceutical Industry China Overview Ribo Life Science's siRNA therapy, vortosiran (BD4059), has received clinical trial approval from the EMA for stroke prevention in atrial fibrillation (SPAF) patients. Vortosiran is... -
EMA CHMP Recommends 12 Medicines for Approval, Including 3 New Hypercholesterolemia Drugs and Therapies for Cholestatic Pruritus and Cerebral Adrenoleukodystrophy
EMA EU Overview The EMA's Committee for Medicinal Products for Human Use (CHMP) adopted positive opinions for twelve medicines at its July 2026 meeting. This includes three new medicines for hypercholesterolemia or mixed dyslipidemia: Ly... -
Complete Guide to Lipid Nanoparticles (LNP): Foundational Technology for Nucleic Acid Delivery Validated by mRNA Vaccine Success
Inside Therapeutics USA Overview Lipid nanoparticles (LNPs) are nanoscale delivery vehicles designed to protect and deliver nucleic acids like mRNA and siRNA into cells, serving as the delivery platform for COVID-19 mRNA vaccines. LNPs o... -
Advances in LNP-Mediated Nucleic Acid Delivery to Respiratory & GI Mucosa: AI Integration for Personalized DDS Future
MDPI Switzerland Overview Lipid nanoparticles (LNPs) are rapidly advancing as a versatile platform to overcome delivery barriers for nucleic acids to respiratory and gastrointestinal mucosal sites. LNPs offer tunable physicochemical prop... -
First PROTAC Approval Validates Targeted Protein Degradation as a Breakthrough Modality for Cancer Treatment
Converge Bio Unknown Overview The FDA approval of vepdegestrant, developed by Arvinas and Pfizer, signifies a major milestone for targeted protein degradation (TPD). This first-in-class PROTAC, approved for ER+/HER2-, ESR1-mutated advanc... -
LG Energy Solution Returns to Profit in Q2, Prepares Dry Electrode Pilot Line for Solid-State Batteries in H2 2026
Investing.com South Korea Overview LG Energy Solution announced a return to profitability in Q2 2026, driven by strong performance in its Energy Storage System (ESS) business. The company revealed plans to prepare a dry electrode process... -
SK On and Factorial Energy Partner to Industrialize Solid-State Batteries, Leveraging Existing Production Facilities
Pluang South Korea and USA Overview SK On and Factorial Energy have signed an MOU to jointly assess the feasibility of manufacturing Factorial's advanced solid-state battery technology within SK On's global lithium-ion battery production...
